A Phase 2 interventional study of Pomalidomide and Pomalidomide in Central Nervous System Neoplasms and Medulloblastoma, sponsored by Celgene. Completed at 22 sites in 5 countries. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2024-04-16.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 172 studies in Brain Neoplasms with a site in France — 38 open to participants now, 53 under way, 6 of them phase 3. Brain Neoplasms · France.
Among the 172 studies in Brain Neoplasms with a site in France, this one is the 79th largest by enrollment of the 132 interventional ones that give a count, is one of 5 that started in 2017, is one of 40 in phase 2, and was the 86th registered.
2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.
Browse Brain Neoplasms studies →38 of the 172 studies in Brain Neoplasms with a site in France are open now. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Bristol-Myers Squibb · Sites in France, United States, Belgium and 10 more countries
Ages 18+
Center Eugene Marquis · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Beta Emitting Accurate Monitored Systems · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 424 Brain Neoplasms studies recruiting now, 285 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.
This study: 1 Year to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
172 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 55 · Phase 3 25
First in 1996; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is above the median of 40 across 1,832 interventional studies indexed under Brain Neoplasms.
Median enrollment 70 across the 132 interventional studies, 100 across the 37 observational. Of the 101 that completed or were terminated, 21 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 172 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
Bristol-Myers Squibb has 7 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
11 of the studies in Brain Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02066220Phase 3Universitätsklinikum Hamburg-EppendorfInternational Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | 2026-12 |
| NCT07558395Institut National de la Santé Et de la Recherche Médicale, FranceEffectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour | 2026-12 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
| NCT06413706Eli Lilly and CompanyA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | 2027-02 |
| NCT07274397Beta Emitting Accurate Monitored SystemsAssessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma | 2027-04-17 |
Add all 11 to your calendar (.ics) → With an account.
Among the 172 studies in Brain Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy, safety and tolerability of pomalidomide in children and young adults aged 1 to \< 21 years with recurrent or progressive primary brain tumors in one of four primary brain tumor types: high-grade glioma (HGG), medulloblastoma, ependymoma and diffuse intrinsic pontine glioma (DIPG).
The study will consist of 4 parallel groups of participants, one for each of the following primary brain tumor types: high-grade glioma, medulloblastoma, ependymoma and DIPG. A Simon's Optimal two-stage study design will be applied to each group and enrollment will occur as follows:
Once treatment has been discontinued, participants will be followed up for up to 5 years from enrollment of the last participant.
Participants who withdraw from either stage for reasons other than disease progression prior to completing Cycle 1 of study treatment will be replaced.
2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.
This study's enrollment of 53 is above the median of 40 across 1,832 interventional studies indexed under Brain Neoplasms.
Browse Brain Neoplasms studies →Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted before Celgene became part of Bristol-Myers Squibb.
Compared within Brain Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Central Nervous System Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To document the degree of tumor at study baseline, the following scan(s) must be obtained:
Subject has adequate bone marrow function defined as:
Subject has adequate renal function defined as:
Subject has adequate liver function defined as:
Subject has adequate pulmonary function defined as:
Females of childbearing potential must agree and meet the following conditions below:
Male subjects must, as appropriate to age and the discretion of the study physician:
Exclusion Criteria:
Subject has previously received (presence of any of the following will exclude a subject from enrollment):
Prior radiation:
Note: True disease progression following prior irradiation therapy must be confirmed by Investigator prior to screening.
Bone marrow transplant:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).
Drug: Pomalidomide
: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
Also known as: CC-4047
Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
Also known as: CC-4047, Pomalyst®
Percentage of Participants With an Objective Response and Long-term Stable Disease
The percentage of participants who achieved either an objective response, defined as a complete response (CR) or partial response (PR) in the first 6 cycles of treatment (or within 3 cycles for DIPG), or long-term stable disease (SD) defined as SD maintained for ≥ 6 cycles (≥ 3 cycles for DIPG), measured from first dose date. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions, and/or persistence of non-target lesions with no progression or decrease in size. SD: A decrease of \< 50% or an increase of \< 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time frame: 6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group
Percentage of Participants Who Achieved an Objective Response (ORR)
Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) within the first 6 cycles of treatment (or within 3 cycles for participants in the DIPG group). Disease assessments were based on MRI and assessed by an independent central review. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time frame: 6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group
Percentage of Participants With Long-term Stable Disease
Long-term stable disease (SD) rate was defined as the percentage of participants who achieved SD maintained for ≥ 6 cycles (or \> 3 cycles for DIPG), measured from the date of first dose of treatment. Disease assessments were based on MRI and assessed by an independent central review. SD: A decrease of \< 50% or an increase of \< 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time frame: 6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group
Duration of Response (DoR)
DoR is defined as the time from the date of the first objective response (complete response \[CR\] or partial response \[PR\]) to disease progression. Participants who did not have disease progression or had not died were censored at the time of their last disease assessment or at the time of start of new anticancer therapy, whichever occurred first. Progressive disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar cerebrospinal fluid (CSF) cytology were previously negative and became positive. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size.
Time frame: From the first dose of pomalidomide to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 71 months)
Kaplan-Meier Estimate of Progression-Free Survival (PFS)
Progression-free survival was defined as the time from the date of first dose of pomalidomide until the date progressive disease (PD) was first observed or until the date of death due to any cause, whichever occurred first. Participants who did not have PD or had not died at the time of analysis were censored at the time of their last disease assessment or at the start of new anticancer therapy, whichever occurred first. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar CSF cytology were previously negative and became positive.
Time frame: From the first dose of pomalidomide to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 71 months)
Kaplan-Meier Estimate of Overall Survival (OS)
Overall survival was defined as the time from the date of the first dose to the date of death (any cause). Participants who were alive were censored at the last known time that the participant was alive.
Time frame: From the first dose of pomalidomide to the date of death due to any cause (Up to 71 months)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Treatment-emergent adverse events were defined as any adverse events (AE) occurring from the first dose of pomalidomide until 28 days after the last dose. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 and according to the following scale: Grade 1: Mild (transient or mild discomfort; no limitation in activity or medical intervention required); Grade 2: Moderate (mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required); Grade 3: Severe (marked limitation in activity, assistance and medical intervention required, hospitalization possible); Grade 4: Life-threatening (extreme limitation in activity, significant assistance or medical intervention required, hospitalization or hospice care probable); Grade 5: Death. Drug-related AEs are those suspected by the Investigator as being related to administration of study drug.
Time frame: From the first dose of pomalidomide until 28 days after the last dose (Up to approximately 72 months)
The study consisted of 4 groups, for each of the following primary brain tumor types: diffuse intrinsic pontine glioma (DIPG), ependymoma, high-grade glioma, and medulloblastoma.
| Milestone | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma |
|---|---|---|---|---|
| Started | 11 | 9 | 23 | 10 |
| Received study drug | 11 | 9 | 22 | 10 |
| Completed | 0 | 0 | 1 | 0 |
| Not completed | 11 | 9 | 22 | 10 |
| Withdrew: Death | 1 | 0 | 1 | 1 |
| Withdrew: Progressive disease | 10 | 9 | 17 | 8 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 |
The percentage of participants who achieved either an objective response, defined as a complete response (CR) or partial response (PR) in the first 6 cycles of treatment (or within 3 cycles for DIPG), or long-term stable disease (SD) defined as SD maintained for ≥ 6 cycles (≥ 3 cycles for DIPG), measured from first dose date. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions, and/or persistence of non-target lesions with no progression or decrease in size. SD: A decrease of \< 50% or an increase of \< 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
| percentage of participants | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma |
|---|---|---|---|---|
| Percentage of Participants With an Objective Response and Long-term Stable Disease | 0 (0.0 to 33.6) | 11.1 (0.3 to 48.2) | 10.5 (1.3 to 33.1) | 0 (0.0 to 33.6) |
Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) within the first 6 cycles of treatment (or within 3 cycles for participants in the DIPG group). Disease assessments were based on MRI and assessed by an independent central review. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
| percentage of participants | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma |
|---|---|---|---|---|
| Percentage of Participants Who Achieved an Objective Response (ORR) | 0 (0.0 to 33.6) | 0 (0.0 to 33.6) | 5.3 (0.1 to 26.0) | 0 (0.0 to 33.6) |
Long-term stable disease (SD) rate was defined as the percentage of participants who achieved SD maintained for ≥ 6 cycles (or \> 3 cycles for DIPG), measured from the date of first dose of treatment. Disease assessments were based on MRI and assessed by an independent central review. SD: A decrease of \< 50% or an increase of \< 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
| percentage of participants | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma |
|---|---|---|---|---|
| Percentage of Participants With Long-term Stable Disease | 0 (0.0 to 33.6) | 11.1 (0.3 to 48.2) | 5.3 (0.1 to 26.0) | 0 (0.0 to 33.6) |
DoR is defined as the time from the date of the first objective response (complete response \[CR\] or partial response \[PR\]) to disease progression. Participants who did not have disease progression or had not died were censored at the time of their last disease assessment or at the time of start of new anticancer therapy, whichever occurred first. Progressive disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar cerebrospinal fluid (CSF) cytology were previously negative and became positive. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size.
| weeks | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma |
|---|---|---|---|---|
| Duration of Response (DoR) | 12.29 (NA to NA) | — | NA (NA to NA) | — |
Progression-free survival was defined as the time from the date of first dose of pomalidomide until the date progressive disease (PD) was first observed or until the date of death due to any cause, whichever occurred first. Participants who did not have PD or had not died at the time of analysis were censored at the time of their last disease assessment or at the start of new anticancer therapy, whichever occurred first. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar CSF cytology were previously negative and became positive.
| weeks | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma |
|---|---|---|---|---|
| Kaplan-Meier Estimate of Progression-Free Survival (PFS) | 11.43 (4.43 to 12.57) | 8.43 (5.57 to 16.14) | 7.86 (5.43 to 8.29) | 8.29 (7.29 to 18.00) |
Overall survival was defined as the time from the date of the first dose to the date of death (any cause). Participants who were alive were censored at the last known time that the participant was alive.
| months | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma |
|---|---|---|---|---|
| Kaplan-Meier Estimate of Overall Survival (OS) | 4.86 (1.02 to 10.91) | 12.02 (2.86 to 20.90) | 5.06 (2.04 to 16.66) | 11.60 (1.74 to 35.32) |
Treatment-emergent adverse events were defined as any adverse events (AE) occurring from the first dose of pomalidomide until 28 days after the last dose. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 and according to the following scale: Grade 1: Mild (transient or mild discomfort; no limitation in activity or medical intervention required); Grade 2: Moderate (mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required); Grade 3: Severe (marked limitation in activity, assistance and medical intervention required, hospitalization possible); Grade 4: Life-threatening (extreme limitation in activity, significant assistance or medical intervention required, hospitalization or hospice care probable); Grade 5: Death. Drug-related AEs are those suspected by the Investigator as being related to administration of study drug.
| Participants | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma |
|---|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 11 | 8 | 21 | 9 |
| TEAE related to study drug | 5 | 7 | 14 | 8 |
| Serious TEAE | 9 | 4 | 14 | 4 |
| Serious TEAE related to study drug | 1 | 0 | 6 | 0 |
| Grade 3/4 TEAE | 8 | 6 | 14 | 6 |
| Grade 3/4 TEAE related to study drug | 3 | 2 | 10 | 4 |
| TEAE leading to death | 5 | 1 | 3 | 1 |
| TEAE leading to dose reduction | 1 | 0 | 3 | 0 |
| TEAE leading to dose interruption | 4 | 3 | 5 | 2 |
| TEAE leading to study drug discontinuation | 2 | 1 | 2 | 0 |
Collected over Participants were assessed for all-cause mortality from their first dose until their study completion (up to approximately 72 months). SAEs and other AEs were assessed from first dose until 28 days after last dose (up to approximately 72 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diffuse Intrinsic Pontine Glioma | 11/11 (100%) | 9/11 (81.8%) | 11/11 (100%) |
| Ependymoma | 6/9 (66.7%) | 4/9 (44.4%) | 8/9 (88.9%) |
| High-grade Glioma | 15/23 (65.2%) | 14/22 (63.6%) | 20/22 (90.9%) |
| Medulloblastoma | 9/10 (90%) | 4/10 (40%) | 9/10 (90%) |
| Event | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/11 | 2/9 | 1/22 | 0/10 |
| HydrocephalusNervous system disorders | 0/11 | 2/9 | 2/22 | 0/10 |
| General physical health deteriorationGeneral disorders | 2/11 | 1/9 | 2/22 | 1/10 |
| HemiparesisNervous system disorders | 0/11 | 0/9 | 3/22 | 0/10 |
| PainGeneral disorders | 0/11 | 1/9 | 0/22 | 0/10 |
| EncephalitisInfections and infestations | 0/11 | 0/9 | 0/22 | 1/10 |
| HyponatraemiaMetabolism and nutrition disorders | 0/11 | 0/9 | 1/22 | 1/10 |
| MonoplegiaNervous system disorders | 0/11 | 0/9 | 0/22 | 1/10 |
| SeizureNervous system disorders | 0/11 | 0/9 | 2/22 | 1/10 |
| Transient ischaemic attackNervous system disorders | 0/11 | 0/9 | 0/22 | 1/10 |
| Event | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 3/11 | 7/9 | 9/22 | 4/10 |
| LeukopeniaBlood and lymphatic system disorders | 3/11 | 6/9 | 8/22 | 3/10 |
| LymphopeniaBlood and lymphatic system disorders | 1/11 | 6/9 | 6/22 | 0/10 |
| VomitingGastrointestinal disorders | 2/11 | 4/9 | 5/22 | 4/10 |
| HeadacheNervous system disorders | 3/11 | 4/9 | 5/22 | 3/10 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/11 | 3/9 | 8/22 | 3/10 |
| AnaemiaBlood and lymphatic system disorders | 1/11 | 3/9 | 7/22 | 2/10 |
| RhinitisInfections and infestations | 0/11 | 3/9 | 1/22 | 0/10 |
| PruritusSkin and subcutaneous tissue disorders | 2/11 | 3/9 | 1/22 | 1/10 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/11 | 3/9 | 2/22 | 2/10 |
The intent-to-treat population includes all enrolled participants, regardless of whether they received any treatment or not
| Age, Continuous(years) | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma | Total |
|---|---|---|---|---|---|
| Median | 7.0 (4 to 12) | 12.0 (4 to 15) | 14.0 (5 to 18) | 10.0 (4 to 17) | 12.0 (4 to 18) |
| Age, Customized(Participants) | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma | Total |
|---|---|---|---|---|---|
| ≥ 1 to < 6 years | 1 | 2 | 1 | 1 | 5 |
| ≥ 6 to < 12 years | 9 | 1 | 5 | 6 | 21 |
| ≥ 12 years | 1 | 6 | 17 | 3 | 27 |
| Sex: Female, Male(Participants) | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma | Total |
|---|---|---|---|---|---|
| Female | 4 | 4 | 8 | 3 | 19 |
| Male | 7 | 5 | 15 | 7 | 34 |
| Ethnicity (NIH/OMB)(Participants) | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 0 | 6 | 1 | 11 |
| Not Hispanic or Latino | 7 | 9 | 13 | 8 | 37 |
| Unknown or Not Reported | 0 | 0 | 4 | 1 | 5 |
| Race/Ethnicity, Customized(Participants) | Diffuse Intrinsic Pontine Glioma | Ependymoma | High-grade Glioma | Medulloblastoma | Total |
|---|---|---|---|---|---|
| American Indian or Alaskan Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 2 | 0 | 3 |
| Black or African American | 0 | 0 | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 10 | 9 | 11 | 8 | 38 |
| Not Collected or Reported | 0 | 0 | 5 | 2 | 7 |
| Other | 0 | 0 | 3 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2017 to primary completion in Sep 2023, 71 months.
Of 44 industry-sponsored phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 71 months is above that.
Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pomalidomide